Guixin Powder Veterinary Grade API is supplied as a multi-route active pharmaceutical ingredient powder whose designation covers downstream processing into tablets, injectable liquids, hard-gelatin or HPMC capsules, dry oral powders, granules, medicated feed premixes, and oral solutions. The powder does not possess intrinsic sterility or a single uniform particle-size specification; those attributes must be matched to the chosen route. The designation does not identify the active moiety, so pharmacological dose, species tolerance, and withdrawal period data must be obtained from the marketing authorization holder or veterinary master file. In the absence of a harmonized public monograph for this specific named material, release testing follows the applicable general chapters of USP and Ph. Eur., with safety limits set by VICH guidance for veterinary medicinal products. Product-specific model codes are assigned by the manufacturing site and are not standardized; any model designation should therefore be verified against the certificate of analysis and the approved specification. Published data for this exact configuration is limited, so the following route-specific limits reflect industrial norms for multi-route veterinary APIs rather than product-specific lot-release data.

What Limits Govern Assay, Residual Solvents, and Elemental Impurities?

Analytical release of the powder covers identity, assay, related substances, residual solvents, elemental impurities, water content, residue on ignition, particle size, and microbial quality. For solid oral and premix applications, a compendial assay range of 98.0% to 102.0% on the anhydrous, solvent-free basis is commonly applied; injectable-grade powder may be tightened to 99.0% to 101.0%. Loss on drying by USP <921> Method Ic is generally ≤1.0%; injectable or lyophilized intermediate powder can require ≤0.5%. Sulfated ash by USP <281> is kept ≤0.1%. Residual solvent levels follow ICH Q3C and VICH GL18; benzene is ≤2 ppm, 1,2-dichloroethane ≤5 ppm, chloroform ≤60 ppm, methanol ≤3000 ppm, and toluene ≤890 ppm. Elemental impurity control follows ICH Q3D and VICH GL19; parenteral routes have lower permitted daily exposures than oral or premix routes, and the final product must be assessed by summation across all components. Microbial enumeration by USP <61> and USP <62> varies by route: non-sterile oral powders and premixes typically require total aerobic microbial count ≤1000 CFU/g and total combined molds/yeasts ≤100 CFU/g, with absence of Escherichia coli and Salmonella. For injectable processing, the API should be sterile or sterilizable; if non-sterile API is used as an intermediate for terminal sterilization or aseptic filtration, the bioburden before sterilization is typically controlled to ≤100 CFU/g to limit pyrogen accumulation. Bacterial endotoxins by USP <85> are not specified for oral solid products but are critical for parenterals; the limit is calculated from the maximum dose, route, and body weight. A powder with endotoxin level of 0.5 EU/mg may be acceptable for a low-dose injectable but unacceptable for a high-dose injectable, so no single generic endotoxin limit can be assigned without the intended dose.

Manufacturing control for the powder typically includes jet milling or pin milling under nitrogen when the API is oxygen-sensitive. Jet milling with compressed nitrogen at inlet pressure 6–8 bar and classifier speed 8000–12000 rpm can reduce D90 to below 75 μm, but it may generate amorphous surface regions that increase moisture uptake. Milled powder should be re-equilibrated at 25°C and 30% RH before packaging to stabilize the particle surface. Batch-to-batch variability in particle size should be controlled to ±15% of the target D50; larger deviations have been observed to alter tablet hardness and dissolution. If the powder is micronized, electrostatic charge can increase and reduce flow; the addition of 0.1–0.3% colloidal silicon dioxide may be required before encapsulation or tableting.

Particle-Size and Tableting Thresholds Observed on Rotary Presses

On production-scale rotary tablet presses, die filling and weight uniformity are controlled by particle-size distribution, bulk density, and flow function. Laser diffraction per ISO 13320:2020 is used to characterize D10, D50, and D90. For direct compression, a D90 ≤75 μm is generally required to achieve content uniformity; if D90 exceeds 150 μm, coarse API particles can segregate in the hopper and produce tablet assay values outside ±5% of label claim. However, over-micronization to D10 ≤5 μm may reduce bulk density below 0.30 g/cm³, increase cohesion, and cause sticking to punch faces. The span (D90−D10/D50) is a critical control: spans above 2.5 are associated with die-fill variability at turret speeds above 45 rpm. Flow is assessed by USP <1174> or by shear-cell testing; free-flowing powder with Carr index ≤25 and Hausner ratio ≤1.25 is preferred for direct compression. Blends containing 0.5 wt% magnesium stearate and 0.2 wt% colloidal silicon dioxide may achieve these values, but the magnesium stearate mixing time should not exceed 5 min because overlubrication can reduce tablet crushing strength by 20–30%. For wet granulation, the powder is granulated in a high-shear mixer using impeller speed 300 rpm and chopper speed 1500 rpm for 3–5 min, followed by fluid-bed drying at inlet air 60°C to final moisture ≤2.0%. Tablet hardness is validated to 40–80 N and friability ≤1.0% by USP <1216>. Disintegration time for immediate-release veterinary tablets is generally ≤15 min in water at 37°C by USP <701>. If the powder is intended for sustained release, direct compression may require a matrix polymer such as hypromellose at 20–30% of tablet weight; the release profile must be controlled by dissolution testing under USP <711>.

Achieving fill weight RSD ≤2.0% on automatic dosator or tamping-pin machines requires sufficient powder flow and stable bulk density. Dosator settings depend on bulk density; a powder with bulk density 0.40–0.60 g/cm³ and tapped density 0.55–0.75 g/cm³ is typically compatible with standard size 0 to 4 capsules. If the API is moisture-sensitive, the powder should be filled at ambient relative humidity below 40% and may require a desiccant pouch in HDPE packaging. Granules for sachet or reconstitutable oral powder should have a broader particle-size range to reduce dust while maintaining dissolution. The finished oral powder should pass through a 1.0 mm screen after dry granulation, with fines below 75 μm limited to 25% of the batch to avoid dusting and segregation.

In medicated premix and granule manufacture, the process-limiting parameter is not compaction but homogeneity and segregation. A double-ribbon mixer operated at 60–70% nominal volume and 10 min mixing time can produce a coefficient of variation ≤5.0% when the API D50 is between 50 μm and 150 μm and the carrier is lactose monohydrate or corncob grit with a particle size 150–250 μm. If the carrier is too fine, segregation under vibration increases; if too coarse, the number of API particles per gram may be insufficient to ensure uniform dose delivery at low concentrations. Sampling at 10 points across the mixer and after transfer to fill hoppers is required to verify that the active concentration remains within ±10% of label claim. Moisture uptake above 60% RH causes caking and flow blockage in auger fillers; packaging in sealed HDPE containers with silica gel desiccant is used when storage humidity cannot be controlled.

Veterinary-specific acceptance criteria may differ from human pharmaceutical limits. For food-producing species, withdrawal period data and marker residue depletion are required by VICH GL48 or regional equivalence; the API powder alone does not provide these data. For multi-species use, the formulation must be evaluated in the target species because hepatic metabolism and renal clearance can alter the safe dose. In feed premix applications, carryover and cross-contamination limits are typically set at 1% of the previous batch or according to regional feed-safety rules; a premix containing the API should be manufactured in dedicated or validated cleaned equipment. Published data for this specific configuration is limited; therefore, site-specific residue and carryover data must be obtained from the manufacturer or marketing authorization holder.

When Guixin Powder Is Directed to Injectable or Solution Dosage Forms

For injectable and solution applications, the API must be dissolved and filtered to remove particulate matter before final container closure. If the powder is not manufactured as sterile, terminal moist-heat sterilization at 121°C for 15 min can be applied only when the active substance demonstrates thermal stability and pH-dependent degradation below 5%. Heat-labile actives require aseptic filtration through a 0.22 μm membrane; filter validation is necessary because hydrophobic active substances can adsorb to polyethersulfone and reduce yield. Subvisible particulate matter must meet USP <788> Method 1: 6000 particles ≥10 μm and 600 particles ≥25 μm per container for small-volume parenterals. Bacterial endotoxin limits per USP <85> are calculated from the maximum dose and route; if the product is administered at 5 mg/kg body weight to a 500 kg animal, the dose is 2500 mg, and an endotoxin content of 0.5 EU/mg corresponds to 1250 EU per animal, which must be compared against the route-specific threshold. If the drug substance is poorly soluble, pH adjustment with 0.1 N hydrochloric acid or sodium hydroxide to 4.0–7.0 may be required, but precipitation can occur if the solution is later diluted with normal saline or phosphate buffer. Compatibility with rubber closures and silicone tubing should be tested at 25°C and 40°C over 24–72 h. For a true solution, particle-size limits in the powder are less critical than solubility, clarity, and dissolution; the solid should dissolve within 10 min under target pH conditions, and dissolution beyond 30 min may require a cosolvent or pH adjustment.

Why Feed-Grade Powder Cannot Be Substituted for a Multi-Route Veterinary API

The principal difference between Guixin Powder Veterinary Grade API and non-compendial feed-grade powders is the level of control over impurities and physical uniformity. Feed-grade powders may be milled without controlled particle-size distribution; they often contain coarse particles above 300 μm, agricultural residues, and total aerobic counts above 10,000 CFU/g. Veterinary Grade API for tablet or injectable processing is manufactured to controlled particle size and low bioburden; for injectable use, the material must be sterile or sterilizable and low in endotoxin. Another difference is residual solvent control: technical-grade material may retain crystallization solvents at percentage levels, whereas pharmaceutical-grade powder is limited to ICH Q3C class-based ppm levels. The powder also differs from purely feed premix APIs in that it must be supported by a drug master file or equivalent regulatory documentation demonstrating stability, batch-to-batch consistency, and method validation under VICH guidelines. The term “for tablets/injections/capsules/powders/granules/premix/solutions” indicates that the manufacturer’s grade is intended to be processed further into those dosage forms; it does not guarantee that every route can be used without additional formulation, sterilization, or stability verification.